nach oben

Clinical and Translational Oncology

Erschienen in:

25.02.2021 | Review Article

Complex roles of discoidin domain receptor tyrosine kinases in cancer

verfasst von: V. Mehta, H. Chander, A. Munshi

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Discoidin domain receptors, DDR1 and DDR2 are members of the receptor tyrosine kinase (RTK) family that serves as a non-integrin collagen receptor and were initially identified as critical regulators of embryonic development and cellular homeostasis. In recent years, numerous studies have focused on the role of these receptors in disease development, in particular, cancer where they have been reported to augment ECM remodeling, invasion, drug resistance to facilitate tumor progression and metastasis. Interestingly, accumulating evidence also suggests that DDRs promote apoptosis and suppress tumor progression in various human cancers due to which their functions in cancer remain ill-defined and presents a case of an interesting therapeutic target. The present review has discussed the role of DDRs in tumorigenesis and the metastasis.

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–34. https://doi.org/10.1016/j.cell.2010.06.011.CrossRefPubMedPubMedCentral

Leitinger B. Discoidin domain receptor functions in physiological and pathological conditions. Int Rev Cell Mol Biol. 2014;310:39–87.CrossRef

El Azreq M-A, Kadiri M, Boisvert M, Pagé N, Tessier PA, Aoudjit F. Discoidin domain receptor 1 promotes Th17 cell migration by activating the RhoA/ROCK/MAPK/ERK signaling pathway. Oncotarget. 2016;7(29):44975.CrossRef

Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1997;1(1):13–23. https://doi.org/10.1016/s1097-2765(00)80003-9.CrossRefPubMed

Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell. 1997;1(1):25–34. https://doi.org/10.1016/S1097-2765(00)80004-0.CrossRefPubMed

Bhatt RS, Tomoda T, Fang Y, Hatten ME. Discoidin domain receptor 1 functions in axon extension of cerebellar granule neurons. Genes Dev. 2000;14(17):2216–28. https://doi.org/10.1101/gad.821600.CrossRefPubMedPubMedCentral

Labrador JP, Azcoitia V, Tuckermann J, Lin C, Olaso E, Manes S, et al. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Rep. 2001;2(5):446–52. https://doi.org/10.1093/embo-reports/kve094.CrossRefPubMedPubMedCentral

Zhang Y, Su J, Yu J, Bu X, Ren T, Liu X, et al. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. J Bone Miner Res. 2011;26(3):604–17. https://doi.org/10.1002/jbmr.225.CrossRefPubMed

Vogel WF, Aszódi A, Alves F, Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol. 2001;21(8):2906–17. https://doi.org/10.1128/MCB.21.8.2906-2917.2001.CrossRefPubMedPubMedCentral

10.

Hou G, Vogel W, Bendeck MP. The discoidin domain receptor tyrosine kinase DDR1 in arterial wound repair. J Clin Invest. 2001;107(6):727–35.CrossRef

11.

Edelhoff S, Sweetser DA, Disteche CM. Mapping of the NEP receptor tyrosine kinase gene to human chromosome 6p21.3 and mouse chromosome 17C. Genomics. 1995;25(1):309–11. doi:https://doi.org/10.1016/0888-7543(95)80144-b.

12.

Dorison A, Dussaule JC, Chatziantoniou C. The Role of Discoidin Domain Receptor 1 in Inflammation. Fibrosis Renal Dis Nephron. 2017;137(3):212–20. https://doi.org/10.1159/000479119.CrossRef

13.

Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metast Rev. 2012;31(1–2):295–321. https://doi.org/10.1007/s10555-012-9346-z.CrossRef

14.

Abdulhussein R, Koo DH, Vogel WF. Identification of disulfide-linked dimers of the receptor tyrosine kinase DDR1. J Biol Chem. 2008;283(18):12026–33.CrossRef

15.

Karn T, Holtrich U, Bräuninger A, Böhme B, Wolf G, Rübsamen-Waigmann H, et al. Structure, expression and chromosmal mapping of TKT from man and mouse: a new subclass of receptor tyrosine kinases with a factor VIII-like domain. Oncogene. 1993;8:3433.PubMed

16.

Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron. 1991;6(5):691–704. https://doi.org/10.1016/0896-6273(91)90167-x.CrossRefPubMed

17.

Leitinger B. Transmembrane collagen receptors. Annu Rev Cell Dev Biol. 2011;27:265–90.CrossRef

18.

Fu HL, Valiathan RR, Arkwright R, Sohail A, Mihai C, Kumarasiri M, et al. Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem. 2013;288(11):7430–7. https://doi.org/10.1074/jbc.R112.444158.CrossRefPubMedPubMedCentral

19.

Schlessinger J. Direct binding and activation of receptor tyrosine kinases by collagen. Cell. 1997;91(7):869–72. https://doi.org/10.1016/s0092-8674(00)80477-8.CrossRefPubMed

20.

Leitinger B, Kwan AP. The discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol. 2006;25(6):355–64. https://doi.org/10.1016/j.matbio.2006.05.006.CrossRefPubMed

21.

Leitinger B. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2. J Biol Chem. 2003;278(19):16761–9. https://doi.org/10.1074/jbc.M301370200.CrossRefPubMed

22.

Ichikawa O, Osawa M, Nishida N, Goshima N, Nomura N, Shimada I. Structural basis of the collagen-binding mode of discoidin domain receptor 2. EMBO J. 2007;26(18):4168–76. https://doi.org/10.1038/sj.emboj.7601833.CrossRefPubMedPubMedCentral

23.

Konitsiotis AD, Raynal N, Bihan D, Hohenester E, Farndale RW, Leitinger B. Characterization of high affinity binding motifs for the discoidin domain receptor DDR2 in collagen. J Biol Chem. 2008;283(11):6861–8. https://doi.org/10.1074/jbc.M709290200.CrossRefPubMed

24.

Carafoli F, Bihan D, Stathopoulos S, Konitsiotis AD, Kvansakul M, Farndale RW, et al. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure. 2009;17(12):1573–81. https://doi.org/10.1016/j.str.2009.10.012.CrossRefPubMedPubMedCentral

25.

Hohenester E, Sasaki T, Giudici C, Farndale RW, Bachinger HP. Structural basis of sequence-specific collagen recognition by SPARC. Proc Natl Acad Sci USA. 2008;105(47):18273–7. https://doi.org/10.1073/pnas.0808452105.CrossRefPubMedPubMedCentral

26.

Xu H, Raynal N, Stathopoulos S, Myllyharju J, Farndale RW, Leitinger B. Collagen binding specificity of the discoidin domain receptors: binding sites on collagens II and III and molecular determinants for collagen IV recognition by DDR1. Matrix Biol. 2011;30(1):16–26. https://doi.org/10.1016/j.matbio.2010.10.004.CrossRefPubMedPubMedCentral

27.

Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006;4(1):1–15.CrossRef

28.

Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol. 2011;178(3):1221–32.CrossRef

29.

Curat CA, Eck M, Dervillez X, Vogel WF. Mapping of epitopes in discoidin domain receptor 1 critical for collagen binding. J Biol Chem. 2001;276(49):45952–8. https://doi.org/10.1074/jbc.M104360200.CrossRefPubMed

30.

Yang SH, Baek HA, Lee HJ, Park HS, Jang KY, Kang MJ, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep. 2010;24(2):311–9. https://doi.org/10.3892/or_00000861.CrossRefPubMed

31.

Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer. 2007;96(5):808–14. https://doi.org/10.1038/sj.bjc.6603614.CrossRefPubMedPubMedCentral

32.

Miao L, Zhu S, Wang Y, Li Y, Ding J, Dai J, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med Oncol. 2013;30(3):626. https://doi.org/10.1007/s12032-013-0626-4.CrossRefPubMed

33.

Valencia K, Ormazabal C, Zandueta C, Luis-Ravelo D, Anton I, Pajares MJ, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res. 2012;18(4):969–80. https://doi.org/10.1158/1078-0432.CCR-11-1686.CrossRefPubMed

34.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203. https://doi.org/10.1016/j.cell.2007.11.025.CrossRefPubMed

35.

Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005;65(17):7591–5. https://doi.org/10.1158/0008-5472.CAN-05-1855.CrossRefPubMed

36.

Lee MS, Jung EA, An SB, Kim YJ, Oh DY, Song JY, et al. Prevalence of mutations in discoidin domain-containing receptor tyrosine kinase 2 (DDR2) in squamous cell lung cancers in Korean patients. Cancer Res Treatment. 2017;49(4):1065–76. https://doi.org/10.4143/crt.2016.347.CrossRef

37.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011;1(1):78–89. https://doi.org/10.1158/2159-8274.CD-11-0005.CrossRefPubMedPubMedCentral

38.

Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, et al. Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2. Clin Cancer Res. 2016;22(14):3663–71. https://doi.org/10.1158/1078-0432.CCR-15-2093.CrossRefPubMed

39.

Fathi Z, Mousavi SAJ, Roudi R, Ghazi F. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: an analysis of Iranian patients. PLoS ONE. 2018;13(7):e0200633. https://doi.org/10.1371/journal.pone.0200633.CrossRefPubMedPubMedCentral

40.

Laval S, Butler R, Shelling AN, Hanby AM, Poulsom R, Ganesan TS. Isolation and characterization of an epithelial-specific receptor tyrosine kinase from an ovarian cancer cell line. Cell Growth Differ. 1994;5(11):1173–83.PubMed

41.

Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res. 2004;10(13):4427–36. https://doi.org/10.1158/1078-0432.CCR-04-0073.CrossRefPubMed

42.

Quan J, Yahata T, Adachi S, Yoshihara K, Tanaka K. Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer. Int J Mol Sci. 2011;12(2):971–82. https://doi.org/10.3390/ijms12020971.CrossRefPubMedPubMedCentral

43.

Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, et al. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer. 2011;129(10):2435–44. https://doi.org/10.1002/ijc.25901.CrossRefPubMed

44.

Deng Y, Zhao F, Hui L, Li X, Zhang D, Lin W, et al. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res. 2017;10(1):50. https://doi.org/10.1186/s13048-017-0333-4.CrossRefPubMedPubMedCentral

45.

Grither WR, Divine LM, Meller EH, Wilke DJ, Desai RA, Loza AJ, et al. TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis. Oncogene. 2018;37(13):1714–29. https://doi.org/10.1038/s41388-017-0043-9.CrossRefPubMedPubMedCentral

46.

Xie R, Wang X, Qi G, Wu Z, Wei R, Li P, et al. DDR1 enhances invasion and metastasis of gastric cancer via epithelial-mesenchymal transition. Tumour Biol. 2016;37(9):12049–59. https://doi.org/10.1007/s13277-016-5070-6.CrossRefPubMed

47.

Hur H, Ham IH, Lee D, Jin H, Aguilera KY, Oh HJ, et al. Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. BMC Cancer. 2017;17(1):87. https://doi.org/10.1186/s12885-017-3051-9.CrossRefPubMedPubMedCentral

48.

Wang Y-G, Xu L, Jia R-R, Wu Q, Wang T, Wei J, et al. DDR2 induces gastric cancer cell activities via activating mTORC2 signaling and is associated with clinicopathological characteristics of gastric cancer. Dig Dis Sci. 2016;61(8):2272–83. https://doi.org/10.1007/s10620-016-4116-3.CrossRefPubMed

49.

Kurashige J, Hasegawa T, Niida A, Sugimachi K, Deng N, Mima K, et al. Integrated molecular profiling of human gastric cancer identifies DDR2 as a potential regulator of peritoneal dissemination. Sci Rep. 2016;6:22371. https://doi.org/10.1038/srep22371.CrossRefPubMedPubMedCentral

50.

Jin H, Ham IH, Oh HJ, Bae CA, Lee D, Kim YB, et al. Inhibition of discoidin domain receptor 1 prevents stroma-induced peritoneal metastasis in gastric carcinoma. Mol Cancer Res. 2018;16(10):1590–600. https://doi.org/10.1158/1541-7786.MCR-17-0710.CrossRefPubMed

51.

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y.CrossRefPubMedPubMedCentral

52.

Park HS, Kim KR, Lee HJ, Choi HN, Kim DK, Kim BT, et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep. 2007;18(6):1435–41. https://doi.org/10.3892/or.18.6.1435.CrossRefPubMed

53.

Olaso E, Ikeda K, Eng FJ, Xu L, Wang L-H, Lin HC, et al. DDR2 receptor promotes MMP-2–mediated proliferation and invasion by hepatic stellate cells. J Clin Invest. 2001;108(9):1369–78. https://doi.org/10.1172/JCI12373.CrossRefPubMedPubMedCentral

54.

Lee J-H, Poudel B, Ki H-H, Nepali S, Lee Y-M, Shin J-S, et al. Complement C1q stimulates the progression of hepatocellular tumor through the activation of discoidin domain receptor 1. Sci Rep. 2018;8(1):4908. https://doi.org/10.1038/s41598-018-23240-6.CrossRefPubMedPubMedCentral

55.

Lee NO, Park JW, Lee JA, Shim JH, Kong SY, Kim KT, et al. Dual action of a selective cyclooxygenase-2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2. J Cancer Res Clin Oncol. 2012;138(1):73–84. https://doi.org/10.1007/s00432-011-1075-0.CrossRefPubMed

56.

Park JW, Lee YS, Kim JS, Lee SK, Kim BH, Lee JA, et al. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(11):1973–83. https://doi.org/10.1007/s00432-015-1967-5.CrossRefPubMed

57.

Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol. 2013;15(6):677–87. https://doi.org/10.1038/ncb2743.CrossRefPubMedPubMedCentral

58.

Ren T, Zhang W, Liu X, Zhao H, Zhang J, Zhang J, et al. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial–mesenchymal transition programme under hypoxia. J Pathol. 2014;234(4):526–37. https://doi.org/10.1002/path.4415.CrossRefPubMed

59.

Vella V, Malaguarnera R, Nicolosi ML, Palladino C, Spoleti C, Massimino M, et al. Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells. Oncotarget. 2017;8(26):43248–70. https://doi.org/10.18632/oncotarget.18020.CrossRefPubMedPubMedCentral

60.

Belfiore A, Malaguarnera R, Nicolosi ML, Lappano R, Ragusa M, Morrione A, et al. A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer. Cell Adhes Migr. 2018;12(4):305–14. https://doi.org/10.1080/19336918.2018.1445953.CrossRef

61.

Slocum E, Craig A, Villanueva A, Germain D. Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Res. 2019;21(1):56. https://doi.org/10.1186/s13058-019-1142-z.CrossRefPubMedPubMedCentral

62.

Baltes F, Caspers J, Henze S, Schlesinger M, Bendas G. Targeting discoidin domain receptor 1 (DDR1) signaling and Its crosstalk with β1-integrin emerges as a key factor for breast cancer chemosensitization upon collagen type 1 binding. Int J Mol Sci. 2020;21(14):4956.CrossRef

63.

Sun X, Gupta K, Wu B, Zhang D, Yuan B, Zhang X, et al. Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulatingadipose stromal interleukin 6 production in mice. J Biol Chem. 2018. https://doi.org/10.1074/jbc.RA117.000672.CrossRefPubMedPubMedCentral

64.

Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, Gao Y, et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. Cell. 2016;166(1):47–62.CrossRef

65.

Das S, Ongusaha PP, Yang YS, Park J-M, Aaronson SA, Lee SW. Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-κB pathway activation. Can Res. 2006;66(16):8123–30. https://doi.org/10.1158/0008-5472.CAN-06-1215.CrossRef

66.

Ren T, Zhang J, Zhang J, Liu X, Yao L. Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients. Med Oncol. 2013;30(1):397. https://doi.org/10.1007/s12032-012-0397-3.CrossRefPubMed

67.

Toy KA, Valiathan RR, Nunez F, Kidwell KM, Gonzalez ME, Fridman R, et al. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):9–18. https://doi.org/10.1007/s10549-015-3285-7.CrossRefPubMedPubMedCentral

68.

Corsa CA, Brenot A, Grither WR, Van Hove S, Loza AJ, Zhang K, et al. The action of discoidin domain receptor 2 in basal tumor cells and stromal cancer-associated fibroblasts is critical for breast cancer metastasis. Cell Rep. 2016;15(11):2510–23. https://doi.org/10.1016/j.celrep.2016.05.033.CrossRefPubMedPubMedCentral

69.

Zhang S, Bu X, Zhao H, Yu J, Wang Y, Li D, et al. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis. J Pathol. 2014;232(4):436–48. https://doi.org/10.1002/path.4311.CrossRefPubMed

70.

Gonzalez ME, Martin EE, Anwar T, Arellano-Garcia C, Medhora N, Lama A, et al. Mesenchymal stem cell-induced DDR2 mediates stromal-breast cancer interactions and metastasis growth. Cell Rep. 2017;18(5):1215–28. https://doi.org/10.1016/j.celrep.2016.12.079.CrossRefPubMedPubMedCentral

71.

Weiner HL, Huang H, Zagzag D, Boyce H, Lichtenbaum R, Ziff EB. Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery. 2000;47(6):1400–9.CrossRef

72.

Ram R, Lorente G, Nikolich K, Urfer R, Foehr E, Nagavarapu U. Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2. J Neurooncol. 2006;76(3):239–48. https://doi.org/10.1007/s11060-005-6874-1.CrossRefPubMed

73.

Ma YS, Wu ZJ, Bai RZ, Dong H, Xie BX, Wu XH, et al. DRR1 promotes glioblastoma cell invasion and epithelial-mesenchymal transition via regulating AKT activation. Cancer Lett. 2018;423:86–94. https://doi.org/10.1016/j.canlet.2018.03.015.CrossRefPubMed

74.

Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, et al. The genomic landscape of schwannoma. Nat Genet. 2016;48(11):1339–48. https://doi.org/10.1038/ng.3688.CrossRefPubMed

75.

Shimada K, Nakamura M, Ishida E, Higuchi T, Yamamoto H, Tsujikawa K, et al. Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer. Cancer Sci. 2008;99(1):39–45. https://doi.org/10.1111/j.1349-7006.2007.00655.x.CrossRefPubMed

76.

Azizi R, Salemi Z, Fallahian F, Aghaei M. Inhibition of didscoidin domain receptor 1 reduces epithelial–mesenchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines. J Cell Physiol. 2019;234(11):19539–52. https://doi.org/10.1002/jcp.28552.CrossRefPubMed

77.

Zhao Z, Zhao S, Luo L, Xiang Q, Zhu Z, Wang J, et al. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition. Br J Cancer. 2020;2020:1–13.

78.

Yan Z, Jin S, Wei Z, Huilian H, Zhanhai Y, Yue T, et al. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein. Biochim Biophys Acta. 2014;1842(9):1350–63. https://doi.org/10.1016/j.bbadis.2014.04.018.CrossRefPubMed

79.

Rudra-Ganguly N, Lowe C, Mattie M, Chang MS, Satpayev D, Verlinsky A, et al. Discoidin domain receptor 1 contributes to tumorigenesis through modulation of TGFBI expression. PLoS ONE. 2014;9(11):e111515. https://doi.org/10.1371/journal.pone.0111515.CrossRefPubMedPubMedCentral

80.

Aguilera KY, Huang H, Du W, Hagopian MM, Wang Z, Hinz S, et al. Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2017;16(11):2473–85. https://doi.org/10.1158/1535-7163.MCT-16-0834.CrossRefPubMedPubMedCentral

81.

Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. Collagen I–mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol. 2008;180(6):1277–89.CrossRef

82.

Huang H, Svoboda RA, Lazenby AJ, Saowapa J, Chaika N, Ding K, et al. Up-regulation of N-cadherin by collagen I-activated discoidin domain receptor 1 in pancreatic cancer requires the adaptor molecule Shc1. J Biol Chem. 2016;291(44):23208–23.CrossRef

83.

Aguilera KY, Rivera LB, Hur H, Carbon JG, Toombs JE, Goldstein CD, et al. Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Can Res. 2014;74(4):1032–44.CrossRef

84.

Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, et al. Discoidin domain receptors: a promising target in melanoma. Pigment Cell Melanoma Res. 2019;32(5):697–707. https://doi.org/10.1111/pcmr.12809.CrossRefPubMed

85.

Xie X, He H, Zhang N, Wang X, Rui W, Xu D, et al. Overexpression of DDR1 promotes migration, invasion, though EMT-related molecule expression and COL4A1/DDR1/MMP-2 signaling axis. Technol Cancer Res Treatment. 2020;19:1533033820973277.

86.

Badiola I, Villace P, Basaldua I, Olaso E. Downregulation of discoidin domain receptor 2 in A375 human melanoma cells reduces its experimental liver metastasis ability. Oncol Rep. 2011;26(4):971–8. https://doi.org/10.3892/or.2011.1356.CrossRefPubMed

87.

Poudel B, Lee Y-M, Kim D-K. DDR2 inhibition reduces migration and invasion of murine metastatic melanoma cells by suppressing MMP2/9 expression through ERK/NF-κB pathway. Acta Biochim Biophys Sin. 2015;47(4):292–8. https://doi.org/10.1093/abbs/gmv005.CrossRefPubMed

88.

Rodrigues R, Roque L, Espadinha C, Pinto A, Domingues R, Dinis J, et al. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncol Rep. 2007;18(4):917–26. https://doi.org/10.3892/or.18.4.917.CrossRefPubMed

89.

Liang Z, Xie WJ, Zhao M, Cheng GP, Wu MJ. DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway. Oncol Lett. 2017;14(6):8114–21. https://doi.org/10.3892/ol.2017.7250.CrossRefPubMedPubMedCentral

90.

Li D, Yang Z, Liu Z, Zou Q, Yuan Y. DDR2 and IFITM1 Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas. Pathol Oncol Res. 2019;25(1):157–67. https://doi.org/10.1007/s12253-017-0314-3.CrossRefPubMed

91.

Xu J, Lu W, Zhang S, Zhu C, Ren T, Zhu T, et al. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma. Cancer Biol Ther. 2014;15(5):612–22. https://doi.org/10.4161/cbt.28181.CrossRefPubMedPubMedCentral

92.

Maeyama M, Koga H, Selvendiran K, Yanagimoto C, Hanada S, Taniguchi E, et al. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer. 2008;113(10):2823–31. https://doi.org/10.1002/cncr.23900.CrossRefPubMed

93.

Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelial–mesenchymal transition. Matrix Biol. 2011;30(4):243–7. https://doi.org/10.1016/j.matbio.2011.03.007.CrossRefPubMedPubMedCentral

94.

Guo J, Zhao C, Yao R, Sui A, Sun L, Liu X, et al. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Exp Ther Med. 2019;17(3):1593–600. https://doi.org/10.3892/etm.2019.7153.CrossRefPubMedPubMedCentral

95.

Curat CA, Vogel WF. Discoidin domain receptor 1 controls growth and adhesion of mesangial cells. J Am Soc Nephrol. 2002;13(11):2648–56. https://doi.org/10.1097/01.asn.0000032419.13208.0c.CrossRefPubMed

96.

Wall SJ, Werner E, Werb Z, DeClerck YA. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem. 2005;280(48):40187–94. https://doi.org/10.1074/jbc.M508226200.CrossRefPubMed

97.

Wall SJ, Zhong ZD, DeClerck YA. The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. J Biol Chem. 2007;282(33):24471–6. https://doi.org/10.1074/jbc.M702697200.CrossRefPubMed

98.

Yeh Y-C, Wu C-C, Wang Y-K, Tang M-J. DDR1 triggers epithelial cell differentiation by promoting cell adhesion through stabilization of E-cadherin. Mol Biol Cell. 2011;22(7):940–53. https://doi.org/10.1091/mbc.E10-08-0678.CrossRefPubMedPubMedCentral

99.

Hansen C, Greengard P, Nairn AC, Andersson T, Vogel WF. Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1. Exp Cell Res. 2006;312(20):4011–8. https://doi.org/10.1016/j.yexcr.2006.09.003.CrossRefPubMed

100.

Assent D, Bourgot I, Hennuy B, Geurts P, Noël A, Foidart J-M, et al. A membrane-type-1 matrix metalloproteinase (MT1-MMP)–discoidin domain receptor 1 axis regulates collagen-induced apoptosis in breast cancer cells. PLoS ONE. 2015;10(3):e0116006. https://doi.org/10.1371/journal.pone.0116006.CrossRefPubMedPubMedCentral

101.

Saby C, Collin G, Sinane M, Buache E, Van Gulick L, Saltel F, et al. DDR1 and MT1-MMP expression levels are determinant for triggering BIK-mediated apoptosis by 3D type I collagen matrix in invasive basal-like breast carcinoma cells. Front Pharmacol. 2019;10:462. https://doi.org/10.3389/fphar.2019.00462.CrossRefPubMedPubMedCentral

102.

Koh M, Woo Y, Valiathan RR, Jung HY, Park SY, Kim YN, et al. Discoidin domain receptor 1 is a novel transcriptional target of ZEB 1 in breast epithelial cells undergoing H-R as-induced epithelial to mesenchymal transition. Int J Cancer. 2015;136(6):E508–20. https://doi.org/10.1002/ijc.29154.CrossRefPubMed

103.

Takai K, Drain AP, Lawson DA, Littlepage LE, Karpuj M, Kessenbrock K, et al. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers. Genes Dev. 2018;32(3–4):244–57. https://doi.org/10.1101/gad.301366.117.CrossRefPubMedPubMedCentral

104.

Ruggeri JM, Franco-Barraza J, Sohail A, Zhang Y, Long D, di Magliano MP et al. Discoidin Domain Receptor 1 (DDR1) is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma. Am J Pathol 2020.

105.

Iwai LK, Payne LS, Luczynski MT, Chang F, Xu H, Clinton RW, et al. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem J. 2013;454(3):501–13. https://doi.org/10.1042/BJ20121750.CrossRefPubMed

106.

Badiola I, Olaso E, Crende O, Friedman SL, Vidal-Vanaclocha F. Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut. 2012;61(10):1465–72. https://doi.org/10.1136/gutjnl-2011-300810.CrossRefPubMed

107.

Kano K, Marin de Evsikova C, Young J, Wnek C, Maddatu TP, Nishina PM, et al. A novel dwarfism with gonadal dysfunction due to loss-of-function allele of the collagen receptor gene, Ddr2, in the mouse. Mol Endocrinol. 2008;22(8):1866–80.CrossRef

108.

Lai SL, Tan ML, Hollows RJ, Robinson M, Ibrahim M, Margielewska S, et al. Collagen induces a more proliferative, migratory and chemoresistant phenotype in head and neck cancer via DDR1. Cancers (Basel). 2019;11(11):1766. https://doi.org/10.3390/cancers11111766.CrossRef

109.

Li S, Zhang Z, Xue J, Guo X, Liang S, Liu A. Effect of hypoxia on DDR1 expression in pituitary adenomas. Med Sci Monitor. 2015;21:2433–8. https://doi.org/10.12659/MSM.894205.CrossRef

110.

Zhong X, Zhang W, Sun T. DDR1 promotes breast tumor growth by suppressing antitumor immunity. Oncol Rep. 2019;42(6):2844–54. https://doi.org/10.3892/or.2019.7338.CrossRefPubMed

111.

Ambrogio C, Darbo E, Lee SW, Santamaria D. A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. Cell Adh Migr. 2018;12(4):394–7. https://doi.org/10.1080/19336918.2018.1445954.CrossRefPubMedPubMedCentral

112.

Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008;599(1–3):44–53. https://doi.org/10.1016/j.ejphar.2008.10.014.CrossRefPubMed

Titel: Complex roles of discoidin domain receptor tyrosine kinases in cancer
verfasst von: V. Mehta
H. Chander
A. Munshi
Publikationsdatum: 25.02.2021
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-021-02552-6

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Complex roles of discoidin domain receptor tyrosine kinases in cancer

Abstract

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

Chronic toxicity and long-term outcome in intraoperative electron radiotherapy as boost followed by whole-breast irradiation

Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial

Expression of bone morphogenetic protein 10 in cases with endometrial carcinoma and its clinical significance

Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie